With Season 4 currently in production, fans remain hopeful that Lupin Season 5 could be a possibility. It may be too early to ...

Catalyst Pharmaceuticals ( NASDAQ: CPRX) said that the company and licensor SERB S.A. signed a settlement agreement with ...

In the past four weeks, the Nifty Pharma index has slipped 5 per cent, as against 0.19 per cent decline in the Nifty 50.

Researchers have found that white lupins could be used as a replacement of soybean meal in growing-finishing pigs’ diets, ...

As part of the settlement, Lupin will receive a license to market generic Firdapse beginning in February 2035.

Pursuant to the terms of the Agreement, Lupin will not market its generic version of FIRDAPSE in the United States any earlier than February 25, 2035, if approved by the U.S. Food and Drug ...

CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.

Indian stock market opened positively as Nifty 50 rose 0.28% and BSE Sensex increased by 0.29%. The market sentiment improved ...

Indian pharmaceutical stocks slipped sharply on Tuesday after US President Donald Trump vowed to slash drug prices ...

Catalyst Pharmaceuticals agreed to settle its litigation against Lupin Pharmaceuticals over Lupin's application to market a generic version of Catalyst's Lambert-Eaton myasthenic syndrome drug.